Transthyretin Amyloidosis (ATTR)
International Symposium on Amyloidosis (ISA) 2026
Congress Details
November 15-18, 2026
Montevideo, Uruguay
The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.
For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Agenda
16 November, 2026
Presentation Type
Time
Location
Title
Presenter
Yoshiki Sekijima
Shinshu University School of Medicine,
Matsumoto, Japan
Presentation Type
Time
Location
Title
Presenter
Sumeet Mitter
Inova Schar Heart and Vascular
Falls Church, VA, USA
17 November, 2026
Presentation Type
Time
Location
Title
Presenter
Juan Pablo Costabel
Instituto Cardiovascular de Buenos Aires
Buenos Aires, Argentina
18 November, 2026
Presentation Type
Time
Location
Title
Presenter
Sumeet Mitter
Inova Schar Heart and Vascular
Falls Church, VA, USA
Alejandra Gonzalez-Duarte
NYU Langone Health, NYU Grossmann School of Medicine
New York, NY
Presentation Type
Time
Location
Title
Related Materials
Transthyretin Amyloidosis (ATTR)
Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial
European Journal of Heart Failure
Transthyretin Amyloidosis (ATTR)
Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis
Journal of Clinical Medicine
Transthyretin Amyloidosis (ATTR)
Impact of Patisiran on Polyneuropathy of Hereditary Transthyretin Amyloidosis in Patients with a V122I or T60A Variant: A Phase IV Multicenter Study
Annals of Medicine
